
News|Articles|May 1, 2002
Ezetimibe added to a statin results in greater LDL reduction
Adding the investigational cholesterol absorption inhibitor ezetimibe to statin therapy results in additional reductions in low-density lipoprotein (LDL) cholesterol of up to 14%.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Myqorzo is now available for rare heart condition at a $108,400 annual price
2
Medicaid tech companies pledge $600 million to help states update systems
3
FAQ: The uncertain future of enhanced ACA premium subsidies and what it means for U.S. healthcare
4
Why the great pharma-MedTech divide is healthcare’s biggest miss
5























